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See related research by Cappabianca et al., http://www.ccforum.com/content/20/1/5In a retrospective study of bleeding patients in cardiac
surgery, Cappabianca et al. [1] observed that the use of
prothrombin complex concentrate (PCC) compared with
fresh-frozen plasma (FFP) was associated with a higher
risk of postoperative renal complications. In the un-
adjusted comparison, acute kidney injury (AKI) inci-
dence was significantly higher in the PCC group, and
use of PCC was an independent predictive factor of AKI
development and the need for renal replacement therapy
in the propensity-adjusted multivariate analysis. Since
prothrombotic effects of PCC are unlikely as the under-
lying mechanism because an increase of thrombo-
embolic events was not observed in the study, the
authors speculate that volume excess given with FFP
and a more hypovolemic balance with PCC in the* Correspondence: christian.wiedermann@asbz.it
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ive effect on kidney function in the FFP group. Interest-
ingly, in the PCC group, use of inotropes was significantly
lower than in the FFP group (p = 0.007) [1]. This may have
contributed to the observed difference in renal risk, since
a recent meta-analysis on perioperative hemodynamic
management associated inotropic drug use with a re-
duction in the incidence of postoperative AKI (odds ra-
tio = 0.52, 95 % confidence interval = 0.34–0.80, p = 0.003,
14 studies, n = 1634 patients; included were two studies in
cardiac surgery, n = 433 patients) [2]. The observed as-
sociation of PCC use with higher risk of AKI may
therefore be due to unknown confounders in this ob-
servational propensity score-matched analysis [3] rather
than due to direct pharmacological effects of PCC.nd Fausto BiancariWe read with great interest this letter from
Wiedermann regarding our recent study [1] investi-
gating the safety and efficacy of PCC as first-line
treatment in bleeding after cardiac surgery. In our
study, we observed an increased incidence of AKI
and renal replacement therapy in the group of
patients receiving PCC compared with those receiv-
ing FFP (31.3 % vs. 23.4 %, p = 0.01 and 3.1 % vs.
1.2 %, p = 0.037, respectively). We originally speculated
that embolic events and especially the hypovolemia
accompanying PCC use could have explained the ob-
served correlation with renal dysfunction. Wiedermannunderlined that the lower AKI rate observed in the FFP
group could have been related to the high rate of ino-
tropes (protective confounders) encountered in the
same patient group rather than the hypovolemic bal-
ance following PCC use. We agree that postoperative
AKI is a consequence of an interplay of different patho-
physiologic mechanisms, and it remains distinctly
possible that inotropes may protect against AKI, ameli-
orating blood pressure and perfusion [4]. In addition,
our study could also have reflected the inherited inabil-
ity of observational investigations in proving causality.
However, the correlation between inotropes ande is distributed under the terms of the Creative Commons Attribution 4.0
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Wiedermann Critical Care  (2016) 20:63 Page 2 of 2AKI is disputed [5], and even in the meta-analysis
by Prowle and colleagues [2, 5] the exact AKI con-
tribution of inotropes and volume fluid resuscitation
was difficult to ascertain. Nevertheless, our study
did not show any significant difference between the
rate of inotropes in the PCC and FFP propensity
matched groups (odds ratio = 0.74, 95 % confidence
interval = 0.50–1.08) [1].
Abbreviations
AKI: acute kidney injury; FFP: fresh frozen plasma; PCC: prothrombin complex
concentrate.
Competing interests
CJW has received fees for speaking and travel reimbursements from
manufacturers of plasma-derived therapies (CSL Behring, Kedrion, Baxter).
Authors’ contributions
CJW developed the concept for the letter and wrote the manuscript. No
other individual or organization made any substantial contribution to the
creation and revision of the letter. This letter is solely the work product of
the author.
References
1. Cappabianca G, Mariscalco G, Biancari F, Maselli D, Papesso F, Cottini M,
Crosta S, Banescu S, Ahmed AB, Beghi C. Safety and efficacy of prothrombin
complex concentrate as first-line treatment in bleeding after cardiac
surgery. Crit Care. 2016;20:5.
2. Prowle JR, Chua HR, Bagshaw SM, Bellomo R. Clinical review: Volume of
fluid resuscitation and the incidence of acute kidney injury—a systematic
review. Crit Care. 2012;16:230.
3. Austin PC, Laupacis A. A tutorial on methods to estimating clinically and
policy-meaningful measures of treatment effects in prospective
observational studies: a review. Int J Biostat. 2011;7:6.
4. Mariscalco G, Lorusso R, Dominici C, Renzulli A, Sala A. Acute kidney
injury: a relevant complication after cardiac surgery. Ann Thorac Surg.
2011;92:1539–47.
5. Patel NN, Rogers CA, Angelini GD, Murphy GJ. Pharmacological therapies for
the prevention of acute kidney injury following cardiac surgery: a systematic
review. Heart Fail Rev. 2011;16:553–67.
